Relja Popovic
0000-0002-6880-0798
Publication & Citation Trends
Publications
0 total
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia
Cited by 0
Semantic Scholar
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Cited by 0
Semantic Scholar
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL OA
Cited by 30
Semantic Scholar
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. OA
Cited by 26
Semantic Scholar
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia OA
Cited by 10
Semantic Scholar
Evidence of a causal effect of genetic tendency to gain muscle mass on uterine leiomyomata OA
Cited by 15
Semantic Scholar
A FinnGen pilot clinical recall study for Alzheimer’s disease OA
Cited by 5
Semantic Scholar
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML OA
Cited by 7
Semantic Scholar
Research Topics
Acute Myeloid Leukemia Research
(34)
Epigenetics and DNA Methylation
(26)
Protein Degradation and Inhibitors
(24)
Histone Deacetylase Inhibitors Research
(19)
Multiple Myeloma Research and Treatments
(18)
Affiliations
AstraZeneca (United Kingdom)
Northwestern University
Novartis (Switzerland)
Midwestern University
Loyola University Medical Center